EMBC
Embecta Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.80
+1.93%Year over year
Reported trailing growth
- Revenue
- -7.6%
- EBITDA
- +6.1%
- EBIT
- -14.2%
- EPS
- +5.1%
- Free cash flow
- +24.4%
- Operating cash flow
- +29.6%
Forward estimates
Based on analyst estimates
- Revenue
- +5.2%
- EBITDA
- -8.9%
- EPS
- +7.8%
Three-year CAGR
- Revenue
- -1.5%
- EBITDA
- -4.1%
- EBIT
- -4.5%
- Net income
- -24.7%
- EPS
- -25.2%
- Free cash flow
- -22.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026